Edition:
India

Lipocine Inc (LPCN.OQ)

LPCN.OQ on NASDAQ Stock Exchange Capital Market

3.50USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
30,403
52-wk High
$5.32
52-wk Low
$3.25

Chart for

About

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product... (more)

Overall

Beta: 1.04
Market Cap(Mil.): $81.66
Shares Outstanding(Mil.): 20.67
Dividend: --
Yield (%): --

Financials

BRIEF-Lipocine says ‍FDA assigned a new prescription drug user fee act goal date of May 8, 2018 for Tlando​

* U.S. FDA extends review for Tlando™; advisory committee meeting date of January 10, 2018 remains unchanged

17 Nov 2017

BRIEF-Lipocine Inc Q3 loss per share $0.22

* Lipocine announces financial and operational results for the third quarter and nine months ended September 30, 2017

08 Nov 2017

BRIEF-Lipocine says FDA has scheduled bone, reproductive and urologic drugs advisory committee meeting on January 10, 2018

* Lipocine -‍ announced FDA has scheduled bone, reproductive and urologic drugs advisory committee meeting on January 10, 2018 to discuss NDA for Tlando​

18 Oct 2017

BRIEF-Lipocine Inc files for mixed shelf of up to $150 million

* Lipocine Inc files for mixed shelf of up to $150 million - SEC filing‍​ Source text for Eikon: (http://bit.ly/2zlVhiU) Further company coverage:

14 Oct 2017

BRIEF-Lipocine - ‍PTAB of USPTO issued a motions decision in interference case between Clarus Therapeutics and Lipocine Inc​

* Lipocine - ‍ PTAB of USPTO issued a motions decision based on each party's motions in interference case between Clarus Therapeutics and Lipocine Inc​

21 Sep 2017

BRIEF-Lipocine announces FDA Advisory Committee meeting for TLANDO

* Lipocine Inc - advisory committee meeting date has not been finalized but will occur prior to PDUFA goal date of February 8, 2018 Source text for Eikon: Further company coverage:

20 Sep 2017

BRIEF-Lipocine announces FDA acknowledgement of Tlando NDA resubmission

* Lipocine announces FDA acknowledgement of Tlando (LPCN 1021) NDA resubmission; PDUFA goal date, February 8, 2018

14 Aug 2017

BRIEF-Lipocine ‍resubmits NDA for oral testosterone product candidate

* Says ‍resubmits NDA for its oral testosterone product candidate, LPCN 1021, for treatment of hypogonadism​

09 Aug 2017

BRIEF-Lipocine posts Q2 loss per share $0.31

* Lipocine announces financial and operational results for the second quarter and six months ended June 30, 2017

07 Aug 2017

BRIEF-Lipocine announces submission of special protocol assessment request to FDA on LPCN 1107, an oral alternative for prevention of preterm birth

* Lipocine Inc - Announces submission of special protocol assessment request to FDA on LPCN 1107, an oral alternative for prevention of preterm birth Source text for Eikon: Further company coverage:

26 Jun 2017

Earnings vs. Estimates